JP2020533382A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020533382A5 JP2020533382A5 JP2020515147A JP2020515147A JP2020533382A5 JP 2020533382 A5 JP2020533382 A5 JP 2020533382A5 JP 2020515147 A JP2020515147 A JP 2020515147A JP 2020515147 A JP2020515147 A JP 2020515147A JP 2020533382 A5 JP2020533382 A5 JP 2020533382A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid sequence
- seq
- sequence identity
- identity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023120187A JP2023139178A (ja) | 2017-09-14 | 2023-07-24 | 癌の組合せ治療 |
| JP2025093685A JP2025131722A (ja) | 2017-09-14 | 2025-06-04 | 癌の組合せ治療 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762558575P | 2017-09-14 | 2017-09-14 | |
| US62/558,575 | 2017-09-14 | ||
| PCT/IB2018/056967 WO2019053611A1 (en) | 2017-09-14 | 2018-09-12 | POLY THERAPY FOR THE TREATMENT OF CANCER |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023120187A Division JP2023139178A (ja) | 2017-09-14 | 2023-07-24 | 癌の組合せ治療 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020533382A JP2020533382A (ja) | 2020-11-19 |
| JP2020533382A5 true JP2020533382A5 (enExample) | 2021-10-21 |
Family
ID=63713944
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020515147A Pending JP2020533382A (ja) | 2017-09-14 | 2018-09-12 | 癌の組合せ治療 |
| JP2023120187A Pending JP2023139178A (ja) | 2017-09-14 | 2023-07-24 | 癌の組合せ治療 |
| JP2025093685A Pending JP2025131722A (ja) | 2017-09-14 | 2025-06-04 | 癌の組合せ治療 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023120187A Pending JP2023139178A (ja) | 2017-09-14 | 2023-07-24 | 癌の組合せ治療 |
| JP2025093685A Pending JP2025131722A (ja) | 2017-09-14 | 2025-06-04 | 癌の組合せ治療 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US11401334B2 (enExample) |
| EP (1) | EP3694878A1 (enExample) |
| JP (3) | JP2020533382A (enExample) |
| CN (1) | CN111108125A (enExample) |
| BR (1) | BR112020005079A2 (enExample) |
| CA (1) | CA3075714A1 (enExample) |
| WO (1) | WO2019053611A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY204234A (en) | 2018-08-27 | 2024-08-16 | Regeneron Pharma | Use of raman spectroscopy in downstream purification |
| CA3140762A1 (en) * | 2019-05-31 | 2020-12-03 | Medimmune, Llc | Combination therapy |
| JP7456075B2 (ja) | 2020-01-03 | 2024-03-27 | ビオシオン インコーポレイテッド | 抗体結合ｂｃｍａ及びその使用 |
| WO2022184082A1 (en) * | 2021-03-03 | 2022-09-09 | Sorrento Therapeutics, Inc. | Antibody-drug conjugates comprising an anti-bcma antibody |
| US20260053939A1 (en) * | 2022-01-25 | 2026-02-26 | Glaxosmithkline Intellectual Property Development Limited | Combination Therapy for Cancer |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| US6083903A (en) | 1994-10-28 | 2000-07-04 | Leukosite, Inc. | Boronic ester and acid compounds, synthesis and uses |
| CA2435146C (en) | 2001-01-25 | 2011-03-29 | The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Formulation of boronic acid compounds |
| US7576206B2 (en) | 2003-08-14 | 2009-08-18 | Cephalon, Inc. | Proteasome inhibitors and methods of using the same |
| US7232818B2 (en) | 2004-04-15 | 2007-06-19 | Proteolix, Inc. | Compounds for enzyme inhibition |
| ATE494298T1 (de) | 2004-04-15 | 2011-01-15 | Proteolix Inc | Verbindungen zur proteasomenzymhemmung |
| EP2261236B1 (en) | 2004-12-07 | 2015-07-15 | Onyx Therapeutics, Inc. | Composition for proteasome inhibition |
| EP2623113B1 (en) | 2005-11-09 | 2017-05-31 | Onyx Therapeutics, Inc. | Compound for enzyme inhibition |
| US7442830B1 (en) | 2007-08-06 | 2008-10-28 | Millenium Pharmaceuticals, Inc. | Proteasome inhibitors |
| SI2318419T2 (sl) | 2008-06-17 | 2025-10-30 | Takeda Pharmaceutical Company Limited | Spojine boronat estra in njihovi farmacevtski sestavki |
| AR075899A1 (es) | 2009-03-20 | 2011-05-04 | Onyx Therapeutics Inc | Tripeptidos epoxicetonas cristalinos inhibidores de proteasa |
| WO2011060179A1 (en) | 2009-11-13 | 2011-05-19 | Onyx Therapeutics, Inc | Use of peptide epoxyketones for metastasis suppression |
| EP2714737A1 (en) | 2011-05-27 | 2014-04-09 | Glaxo Group Limited | Bcma (cd269/tnfrsf17) -binding proteins |
| UA112434C2 (uk) * | 2011-05-27 | 2016-09-12 | Ґлаксо Ґруп Лімітед | Антигензв'язувальний білок, який специфічно зв'язується з всма |
| TWI679212B (zh) | 2011-11-15 | 2019-12-11 | 美商安進股份有限公司 | 針對ｂｃｍａ之e3以及ｃｄ３的結合分子 |
| MX353603B (es) | 2012-02-28 | 2018-01-19 | Cydex Pharmaceuticals Inc | Composiciones de ciclodextrina alquilada y procesos para preparar y utilizar las mismas. |
| AU2013246443B2 (en) | 2012-04-11 | 2017-04-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric antigen receptors targeting B-cell maturation antigen |
| UY35091A (es) | 2012-10-24 | 2014-05-30 | Onyx Therapeutics Inc | Formulaciones de liberacion modificada para oprozomib |
| EP2914628A1 (en) | 2012-11-01 | 2015-09-09 | Max-Delbrück-Centrum für Molekulare Medizin | An antibody that binds cd269 (bcma) suitable for use in the treatment of plasma cell diseases such as multiple myeloma and autoimmune diseases |
| TW201425336A (zh) | 2012-12-07 | 2014-07-01 | Amgen Inc | Ｂｃｍａ抗原結合蛋白質 |
| US9243058B2 (en) | 2012-12-07 | 2016-01-26 | Amgen, Inc. | BCMA antigen binding proteins |
| JP6636803B2 (ja) | 2013-02-05 | 2020-01-29 | エンクマフ エスアーエールエル | Ｂｃｍａに対する抗体の選択のための方法 |
| AR095374A1 (es) | 2013-03-15 | 2015-10-14 | Amgen Res Munich Gmbh | Moléculas de unión para bcma y cd3 |
| GB201317928D0 (en) | 2013-10-10 | 2013-11-27 | Ucl Business Plc | Molecule |
| EP3131927B8 (en) | 2014-04-14 | 2020-12-23 | Cellectis | Bcma (cd269) specific chimeric antigen receptors for cancer immunotherapy |
| JP6285274B2 (ja) | 2014-04-28 | 2018-02-28 | 株式会社ブリヂストン | バイアスタイヤ及びその製造方法 |
| GB201409471D0 (en) * | 2014-05-28 | 2014-07-09 | Euro Celtique Sa | Pharmaceutical composition |
| AU2015292744C1 (en) | 2014-07-21 | 2021-01-21 | Novartis Ag | Treatment of cancer using humanized anti-BCMA chimeric antigen receptor |
| EP3172231B1 (en) | 2014-07-24 | 2021-05-05 | Bluebird Bio, Inc. | Bcma chimeric antigen receptors |
| EP2982692A1 (en) | 2014-08-04 | 2016-02-10 | EngMab AG | Bispecific antibodies against CD3epsilon and BCMA |
| MA40457A (fr) * | 2014-08-05 | 2017-06-14 | Exelixis Inc | Combinaison de médicaments pour traiter le myélome multiple |
| EP3023437A1 (en) | 2014-11-20 | 2016-05-25 | EngMab AG | Bispecific antibodies against CD3epsilon and BCMA |
| CN113698497A (zh) | 2014-12-05 | 2021-11-26 | 纪念斯隆-凯特琳癌症中心 | 靶向b-细胞成熟抗原的嵌合抗原受体及其用途 |
| HRP20210582T1 (hr) | 2014-12-05 | 2021-09-03 | Memorial Sloan Kettering Cancer Center | Antitijela koja ciljaju antigen sazrijevanja b-stanice i postupci uporabe |
| HUE057285T2 (hu) * | 2015-04-13 | 2022-04-28 | Pfizer | Terápiás ellenanyagok és alkalmazásaik |
| CA2992797A1 (en) * | 2015-08-03 | 2017-02-09 | Engmab Sarl | Monoclonal antibodies against bcma |
| EP3147954A1 (en) | 2015-09-22 | 2017-03-29 | Nokia Technologies Oy | Photodetector with conductive channel made from two dimensional material and its manufacturing method |
| ES2913208T3 (es) * | 2015-12-01 | 2022-06-01 | Glaxosmithkline Ip Dev Ltd | Tratamientos de combinación y usos y métodos de los mismos |
-
2018
- 2018-09-12 BR BR112020005079-2A patent/BR112020005079A2/pt unknown
- 2018-09-12 CA CA3075714A patent/CA3075714A1/en active Pending
- 2018-09-12 CN CN201880060081.0A patent/CN111108125A/zh active Pending
- 2018-09-12 EP EP18779780.8A patent/EP3694878A1/en active Pending
- 2018-09-12 WO PCT/IB2018/056967 patent/WO2019053611A1/en not_active Ceased
- 2018-09-12 US US16/646,836 patent/US11401334B2/en active Active
- 2018-09-12 JP JP2020515147A patent/JP2020533382A/ja active Pending
-
2022
- 2022-06-22 US US17/846,950 patent/US12234293B2/en active Active
-
2023
- 2023-07-24 JP JP2023120187A patent/JP2023139178A/ja active Pending
-
2025
- 2025-01-22 US US19/033,609 patent/US20250163172A1/en active Pending
- 2025-06-04 JP JP2025093685A patent/JP2025131722A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024167313A5 (enExample) | ||
| JP2020500538A5 (enExample) | ||
| JP2017528476A5 (enExample) | ||
| JP2021529557A5 (enExample) | ||
| JP2020533383A5 (enExample) | ||
| IL257281A (en) | Anti-pd-1 antibodies and methods of using them | |
| MX2025004236A (es) | Anticuerpo anti proteina reguladora de se?ales alfa (sirpalfana) | |
| JP2020508303A5 (enExample) | ||
| RU2018123717A (ru) | Комбинированные лечения, их применения и способы | |
| JP2018507220A5 (enExample) | ||
| PE20090518A1 (es) | Proteinas enlazantes de antigenos que enlazan al receptor de la interleucina 18 (il-18) | |
| NZ603972A (en) | Anti-fgfr2 antibodies | |
| JP2021501579A5 (enExample) | ||
| RU2011105062A (ru) | Нейтрализующие антитела против вируса гриппа а и их использование | |
| JP2017534577A5 (enExample) | ||
| JP2022525377A5 (enExample) | ||
| JP2018535650A5 (enExample) | ||
| FI3740504T3 (fi) | CD70-yhdistelmähoito | |
| JP2019504032A5 (enExample) | ||
| RU2020115713A (ru) | Конъюгаты анти-cd71 активируемое антитело - лекарственное средство и способы их применения | |
| RU2588467C3 (ru) | Стабильные и растворимые антитела, ингибирующие vegf | |
| JP2022516351A5 (enExample) | ||
| RU2021103288A (ru) | МОЛЕКУЛЫ СО СПЕЦИФИЧНОСТЬЮ В ОТНОШЕНИИ CD79 и CD22 | |
| JP2016538318A5 (enExample) | ||
| JP2011528902A5 (enExample) |